ABSTRACT
INTRODUCTION
Staphylococcus aureus and coagulase negative staphylococci (CNS) are recognized to be causing nosocomial and communityacquired infections worldwide. A great concern related to these microorganisms is their ability to develop resistance to antibiotics which originally were active against these species.
1,2,3 Although β-lactam antibiotics are the main compounds used to treat infections due to staphylococci, macrolides, lincosamides e streptogramins type B (MLS B ) antibiotics are also widely used to treat staphylococcal infections. These antibiotics exert similar inhibitory effects on bacterial protein synthesis, but they are chemically distinct. 4, 5 MLS B resistance can be caused by several mechanisms, but the predominant form is target modification mediated by ermA, ermB e ermC (erythromycin ribosome methylase) genes. 4, 5 The erm genes encode enzymes that confer inducible or constitutive resistance to MLS B agents via methylation of the 23S rRNA, thereby reducing binding by MLS B agents to the ribosome. 6, 7 Constitutive MLS B resistance can be detected by the disk diffusion test in laboratorial routine. 8 Strains with constitutive MLS B resistance show high-level in vitro cross resistance among MLS B drugs. However, staphylococci isolates with inducible MLS B resistance demonstrate clear in vitro resistance to 14 and 15-member macrolides (e.g., erythromycin), while they seem to be susceptible to 16-member macrolides, lincosamides and streptogramins type B. Therefore, strains can show in vitro erythromycin resistance and false clindamycin susceptibility, because the conventional disk-diffusion may fail to detect inducible MLS B resistance. 4, 9, 10 The Clinical and Laboratory Standards Institute (CLSI) developed a phenotypic method (the double-disk diffusion test (D test) to screen for inducible resistance. 11 However, the polymerase chain reaction (PCR) with specific primers is a genotypic method used to confirm the presence of the MLS B genes, ermA, ermB e ermC. 12 The risk for therapeutic failure is increased as constitutive resistance may raise from iMLS B during the course of clindamycin therapy in patients with severe staphylococci infections. 11 The objective of this study was to determine the prevalence of the MLS B genes in Staphylococcus aureus and coagulase negative staphylococci from patients attending the Hospital de Clínicas de Porto Alegre (HCPA).
MATERIALS AND METHODS

Bacterial isolates
Isolates of S. aureus and of CNS were collected from consecutive clinical specimens sent to the of microbiology laboratory of the HCPA. The period of the study was between September and October 2007. The bacterial identification was performed through Gram's technique and catalase and coagulase tests. Isolates were stored in glycerol broth at -20°C until use. 
Susceptibility tests
ermA, ermB and ermC gene detection
A direct colony suspension of the culture equivalent to a 1.0 McFarland standard was prepared in 500 µL of 10 mM Tris-1 mM EDTA (pH 8.0), vortexed, and boiled for 10 min an aliquot of 5 µL of the suspension was used for each 25 µlL reaction mixture. 13 PCR assays and primers specifi c from the ermA, ermB and ermC resistance genes used in this study have been previously described by Gerard, Lina et al. (Table 1 ). 14 Each reaction was carried out in a fi nal volume of 25 µL and included 10 x PCR buffer (pht®); 3 mM of MgCl 2 (pht®); 5 µM of each ermA, ermB and ermC forward and reverse primers (Invitrogen®); RNAse and DNAse free water; 1.25 U of Taq DNA polymerase (pht®); 2.5 mM of each dATP, dTTP, dCTP, and dGTP (ABgene®); and 5 µL of DNA. The PCR mixture was subjected to thermal cycle (30 cycles of 30 s at 94°C as the denaturation step, 30 s at 57°C as the annealing step, and of 5 min at 72°C as the extension step) with a JMR® PTC-100. The PCRamplifi ed reaction mixture was resolved by electrophoresis through a 2% agarose gel containing ethidium bromide in Tris-borate-EDTA buffer at 12 V/cm for 30 min. The gel was visualized under UV light and the sizes of the amplifi cation products were estimated by comparison with 100 bp molecular size standard ladder.
Three clinical samples with positives results for each of the three genes were submitted to sequencing and analyzed by BLAST and Chromas and DDBJ/EMBL/ GenBank. These isolates were used as positive control in all experiments. All the 152 strains were tested for the presence of MLS B resistance genes and 77 (50.1%) contained one or more erm genes (Figure 1 ). The ermA gene was detected in 44 isolates (41 S. aureus and three CNS), the ermB gene was found in only one isolate of S. aureus and the ermC gene was detected in 28 isolates (four S. aureus and 24 CNS). Combination of erm genes was detected in 4 CNS isolates (Graphics 1 and 2). For S. aureus isolates with cMLS B resistance phenotype, 36 presented the ermA gene, only one exhibited the ermB gene and three had the ermC gene. Moreover, in three of the S. aureus isolates with iMLS B resistance phenotype, two isolates were ermA positive and one was ermC positive. The ermC gene was identifi ed in 20 isolates of CNS with cMLS B resistance phenotype and in two isolates of CNS with iMLS B resistance phenotype. Seven (six S. aureus and one CNS) isolates with cMLS B resistance phenotype did not present any of the three erm genes (Table 1 ). Resistance to non-MLS B antibiotics in S. aureus and CNS isolates with erm genes was higher in relation to the isolates without the erm genes: chloramphenicol (p = 0.004), doxycycline (p < 0.001), gentamicin (p < 0.001), levofl oxacin (p < 0.001), oxacillin (p < 0.001), rifampin (p < 0.001) and, trimethoprim-sulfamethoxazole (p < 0.001). Of the 77 isolates who harbored erm genes, 65 (40 S. aureus and 25 CNS) were multidrug resistant (resistant to fi ve or more antimicrobial class). The overall range of multiresistance among the staphylococci strains studied was 48.2%.
DISCUSSION
The incidence of constitutive and inducible MLS B resistance may vary according to different geographic region and even from hospital to hospital or patient group. This variability is usually associated with the inconsistent use of erythromycin in different institutions; the origin of the isolate (nosocomial versus community acquired); patient age and clinical samples. 15, 16 In our study 53.3% of staphylococci presented one of three MLS B resistance phenotypes. In fact, cMLS B resistance phenotype was the most common (46.7%) and iMLS B and MS B phenotype were each detected in only 3.3% of the staphylococci.
In a study conduced in 4% and cMLS B 3.2%) . 16 In contrast, the cMLS B resistance phenotype was most frequent (46.9%) as compared to iMLS B (30.2%) in France. 14 In Turkey it was demonstrated that the prevalence of the cMLS B phenotype is higher than that of the iMLS B phenotype and the MS B phenotype is low, data similar to our study. 15, [18] [19] [20] A previous study conducted in our city evaluated 200 CNS and showed that only 2.5% of isolates presented the iMLS B resistance phenotype. 21 Therefore, one could speculate that the prevalence of the inducible phenotype is low in our city.
Despite the fact that there is geographic variability among MLS B resistance phenotypes, the prevalence of erm genes has been reported to be similar in various countries. According to our fi ndings, the ermA gene was the most prevalent among the S. aureus isolates (43.6%) and the ermC gene was the most prevalent among the SCN isolates (37.9%). Only three isolates of staphylococci presented the ermB gene (2.0%). The presence of more than one erm gene was not detected in S. aureus but it was observed in four SCN isolates. According to Martineau et al., in Canada, 20 .9% of the S. aureus were positive for the ermA gene and 66% of CNS were positive for the ermC gene, demonstrating that the prevalence of the ermA gene in S. aureus is slightly lower in comparison to other studies. 22 A multicenter study in 24 European university hospitals confi rmed the high prevalence of ermA gene and the low prevalence of ermC and ermB genes among 851 S. aureus. 23 Lina et al. found 63.2% of S. aureus with ermA gene positive and 44% of CNS strains ermC gene positive, while the ermB gene was present in only 1% of staphylococci.
14 The results reported by Westh et al. in Denmark, also showed a high prevalence of the ermA gene in S. aureus isolates and the ermC gene in CNS strains, as well as a low prevalence for the ermB gene. 24 In our study, the ermB gene was also detected in a small percentage of staphylococci isolates. This gene is generally found in animal staphylococci strains. 6, 14, 17 In the present study, eight isolates (three S. aureus and fi ve SCN) susceptible to erythromycin proved to carry erm genes (seven ermA e one ermC). The presence of erm genes among isolates of staphylococci susceptible to erythromycin had already been demonstrated in another study. 22 This may be due to the lack of expression of erm genes due to factors which down regulate the expression of this gene. 22, 23 In our study we found six S. aureus isolates and one CNS resistant to erythromycin and clindamycin but with negative genotypic test. These results were probably associated with the presence of other genes, such as msrA and msrB, with low frequency in Staphylococci species isolated form humans, 25 which were not evaluated in this study. We detected three S. aureus resistant to clindamycin and susceptible to erythromycin, which did not harbor erm genes. In a study conducted by Lina and et al., the only SCN sample that presented this susceptibility profi le was positive for the genes linA and linA´.
14 These genes confer lincosamides resistance only in S. heamolyticus and S. aureus. Incidence of staphylococci with lincosamide resistance but without resistance to macrolides and streptogramins is usually very low.
14,26
CONCLUSION
The aim of this study was to determine the prevalence of the MLS B phenotypes and genes in Staphylococcus aureus and coagulase-negative staphylococci from patients receiving care at our hospital. We found that constitutive MLS B resistance was the most prevalent phenotype in staphylococci; ermA was the most prevalent gene in S. aureus strains, whereas ermC was the most frequent gene in CNS isolates. Therefore, staphylococci with resistance to MLS B are usually detected directly in routine susceptibility test and the "D test" is not required to be performed in most of our isolates. However, other regions in our country may not present the same resistance profi le as ours and, therefore, surveillance studies are warranted in different institutions.
